Table 1.
Patient characteristics
| Age (years) | |
| Median (range) | 63 (36–80) |
| Gender | |
| Male | 35 |
| Female | 31 |
| Performance status | |
| 0/1/2 | 62/3/1 |
| Body Mass Index (kg/m2) | |
| Median (range) | 21.7 (15.1-33.7) |
| Location of primary tumor | |
| Colon | 36 |
| Rectum | 30 |
| Histological type | |
| Well, Moderately | 58 |
| Poorly, Mucinous | 8 |
| Detection of unresectable tumor | |
| Synchronous | 46 |
| Metachronous | 20 |
| The number of organs affected by metastasis | |
| One organ | 44 |
| More than one organ | 22 |
| Regimen of first-line chemotherapy | |
| FOLFOX | 34 |
| CapeOX | 19 |
| FOLFIRI | 7 |
| Others | 6 |
| Molecular targeted therapy | |
| No | 29 |
| Yes | 37 |
| AGR | |
| Median (range) | 1.254 (0.849-1.840) |
| NLR | |
| Median (range) | 2.407 (0.580-7.644) |
| GPS | |
| 0/1/2 | 42/12/9 |
FOLFOX: 5-fluorouracil + leucovorin + oxaliplatin; CapeOX: capecitabine + oxaliplatin; FOLFIRI: 5-fluorouracil + leucovorin + irinotecan; AGR: albumin to globulin ratio; NLR: neutrophil to lymphocyte ratio; GPS: Glasgow prognostic score.